Ten Questions for Westminster: A CRISPR Briefing for People Who Write the Rules

Gene editing arrives in policy conversations in two unhelpful forms: as a miracle, or as a hazard. Neither is much use to the people who have to write statutory instruments, scrutinise budgets or answer constituents' letters. What follows is a deliberately plain briefing, structured as ten questions that anyone working in or around Westminster and the devolved administrations should be able to handle. The answers are short by design. Where a question has no settled answer, that is stated rather than smoothed over.

1. What is being edited, and can the change be inherited?

The most important distinction in the field is between somatic and heritable editing. Somatic editing alters cells in a living patient — blood, liver, eye — and the change does not pass to children. Heritable editing would alter embryos or gametes and would affect descendants. UK law currently permits somatic research and treatment under medicinal product rules and prohibits implanting a genetically modified embryo for reproduction. Almost every policy debate becomes clearer once the speaker says which of the two they mean.

2. How do we know the edit landed in the right place?

Editing tools can, in principle, cut at unintended sites, and can also produce large rearrangements that simple sequencing may miss. Regulators therefore expect developers to characterise off-target activity using several complementary methods and to demonstrate that the chosen approach is proportionate to the risk. The honest position is that measurement has improved markedly, and that no assay can prove a negative absolutely. Policy discussion should focus on what evidence standard is required, not on whether risk can be eliminated.

3. What is the difference between a trial and an NHS treatment?

A clinical trial is authorised to generate evidence, usually in a small and carefully selected group. A commissioned treatment is one the health service has decided to pay for. The two are governed by different processes, and a positive trial result does not automatically produce availability. Ministers are frequently asked to announce cures; the machinery that follows is slower, and saying so early prevents disappointment later.

4. How does the MHRA decide a medicine is safe enough?

The MHRA authorises clinical trials and licenses medicines, assessing quality, safety and efficacy against the evidence supplied. Cell and gene therapies bring particular complications: small trial populations, single-arm designs, and products that cannot be easily withdrawn once infused. The agency has been modernising trial regulation and developing routes for advanced therapies, and further reform is in train. For scrutiny purposes, the useful question is not whether the MHRA is strict but whether its evidentiary expectations match the irreversibility of the product.

5. How does NICE decide whether the NHS can afford it?

Cost-effectiveness appraisal is the standard route, with a highly specialised technologies pathway for very rare conditions and the Innovative Medicines Fund used to support early access while evidence accrues. One-off therapies strain the model: the entire cost lands in year one while the benefit accrues over decades, and outcome data may take years to mature. Expect continuing argument about outcome-based payment arrangements and about who carries the risk if a treatment fails to deliver.

6. What counts as meaningful consent for an irreversible therapy?

Consent for a one-off treatment is not like consent for a course of tablets. Patients must weigh uncertain long-term effects, demanding conditioning regimes, and lifelong follow-up obligations, often while unwell and under time pressure. Good practice involves genuinely independent discussion, accessible materials, and explicit attention to the possibility that a patient feels they have no alternative. Consent is a process, and commissioners should fund it as one.

7. Who is responsible for patients twenty years after treatment?

Long-term follow-up is the least glamorous obligation in the field. Guidance has long pointed to monitoring measured in decades, with fifteen years a common benchmark, and registers exist to capture outcomes. But patients move, services reorganise, and clinical responsibility can become diffuse. There is a strong case for clarity in service specifications about who holds the duty, how data are collected, and what happens when a trial sponsor's interest ends.

8. Will access be equal across the four nations?

Health is devolved, so a therapy available in England may be assessed and commissioned on a different timetable elsewhere. Within England, distance from a specialist centre remains a practical barrier for treatments requiring repeated travel and apheresis. Local health leaders should treat travel, accommodation and time off work as part of the intervention, not as a welfare afterthought. Equity of access is a commissioning decision, not a by-product of scientific progress.

9. What rules now govern gene-edited food and farm animals?

The Genetic Technology (Precision Breeding) Act 2023 created a separate regulatory route in England for organisms whose genetic changes could have arisen through traditional breeding. Implementation has been phased, with the Food Standards Agency developing a register and authorisation process, and the devolved administrations taking differing approaches. Two things follow for scrutiny: the rules are not identical across the UK, and trade friction may arise from divergence. Precision breeding is also not the same as transgenic modification, a distinction that public communication has often blurred.

10. How should ministers read public opinion on gene editing?

Surveys consistently suggest that attitudes are conditional rather than fixed — support depends heavily on purpose, on who benefits, and on whether people believe regulation is independent. The lesson for policymakers is that trust is built through transparency about uncertainty, including occasions when an intervention is not recommended. Overclaiming in a press release is cheap; losing public confidence is not.

The test to apply

A useful discipline for anyone preparing a brief or a speech is to ask three things of every claim: what is being edited, what evidence supports it, and who decides. Those three questions cut through most of the noise. The science will continue to move quickly. The institutional response does not have to be fast, but it does need to be accurate.